Drug that blocks TSLP to reduce COPD flare airway inflammation
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This Phase 2 trial tests whether blocking TSLP can reduce inflammation in the airways of people with COPD, especially around flare-ups. If you often need prednisone and/or antibiotics for COPD exacerbations, this study may help determine a new treatment approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 40 or older and have a confirmed COPD diagnosis
- Have smoked at least 10 pack-years total (current or past smoker)
- Have COPD breathing test results in a specific range: FEV1 after inhaler between 30% and under 80% predicted, and at least 1.0 liter
- Use a stable long-term inhaler plan (LAMA plus LABA, with or without an inhaled steroid) for at least 3 months
- Have had at least one COPD flare in the past 12 months needing prednisone and/or antibiotics
- Be able to use inhalers correctly and have at least 70% daily inhaler compliance during screening/run-in
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests tezepelumab, an injected medication, for people with moderate to very severe COPD who still have flare-ups despite using standard inhalers. It may help reduce flare-ups and improve breathing for those with higher eosinophil levels.
This study tests a new medication called tezepelumab (given as a shot) to see if it can reduce COPD flare-ups in people with moderate to very severe COPD who have had recent flare-ups despite using inhalers. It may be an option for those with higher levels of eosinophils (a type of white blood cell) in their blood.
This trial tests a new medicine, QL2302, to see how well it works compared to an approved treatment called Tezspire for people with severe asthma. If you have asthma that is not well controlled despite using daily inhalers and other medications, you may be able to join.
This study tests a drug called tezepelumab for people with severe asthma that is not well controlled with current treatments. It aims to see if adding this drug can reduce asthma attacks and improve symptoms.
This study tests if the drug mepolizumab can reduce mucus blockages in the airways of people with COPD and frequent flare-ups. It may help improve breathing and reduce flare-ups.
This trial tests a new biologic drug (tezepelumab) to see if it improves symptoms in people with both chronic sinusitis with nasal polyps and severe asthma. The goal is to reduce inflammation and help you breathe better. Participants must not have had prior sinus surgery.
Hear when a new COPD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.